multilayered-biological-framework-outlines-current-and-emerging-triple-negative-breast-cancer-therapies
Multilayered Biological Framework Outlines Current and Emerging Triple-Negative Breast Cancer Therapies

Multilayered Biological Framework Outlines Current and Emerging Triple-Negative Breast Cancer Therapies

Triple-negative breast cancer represents approximately 10 to 20 percent of all diagnosed breast malignancies and continues to pose profound clinical challenges because it lacks estrogen receptor expression, progesterone receptor expression, and human epidermal growth factor receptor 2 amplification. This distinct receptor-negative profile historically eliminated the utility of endocrine interventions and conventional HER2-targeted regimens, leaving systemic cytotoxic chemotherapy as the longstanding foundation of clinical management. However, profound underlying genomic, transcriptomic, and microenvironmental heterogeneity—characterized by ubiquitous TP53 alterations, recurrent PIK3CA mutations, defective homologous recombination repair, and variable immune infiltration—causes starkly divergent patient trajectories. To address the limitations of conventional classifications that categorize treatments strictly by individual drug classes or isolated molecular subtypes, researchers led by Zi-Xun Wang, Zhi-Ming Shao, and colleagues have synthesized an extensive three-layer biological framework in the Journal of Hematology & Oncology. Their analytical model systematically organizes therapeutic evidence across tumor-cell-intrinsic vulnerabilities, local tumor microenvironmental dynamics, and host-level macroenvironmental modifiers to guide durable precision oncology.

Within this restructured therapeutic landscape, cytotoxic chemotherapy is no longer approached as an indiscriminate standalone strategy but rather as an optimized backbone for rational combinations, timing schedules, and risk-adapted treatment intensification. In the neoadjuvant curative setting, the addition of platinum agents has consistently elevated pathological complete response rates across landmark clinical investigations, including CALGB 40603, GeparSixto, BrighTNess, and HELEN-001. Conversely, the clinical utility of platinum in the adjuvant setting remains divergent; the NRG-BR003 trial failed to meet its primary survival endpoint while introducing increased high-grade toxicity, contrasting with favorable outcomes documented in trials like PATTERN and CITRINE. Evidence indicates that platinum sensitivity is most pronounced in tumors harboring germline BRCA mutations or enriched homologous recombination deficiency, though investigators emphasize that homologous recombination deficiency metrics, platinum responsiveness, and targeted enzyme vulnerability are biologically related rather than interchangeable. Beyond platinum integration, cytotoxic optimization encompasses dose-dense schedules, anthracycline-sparing regimens, metronomic maintenance, and post-surgical capecitabine tailored specifically for patients presenting with residual invasive disease after neoadjuvant treatment.

Antibody-drug conjugates have rapidly emerged as a potent therapeutic class that leverages targeted monoclonal antibodies to internalize cytotoxic payloads directly into malignant cells. The Trop-2-directed conjugate sacituzumab govitecan is supported by robust phase III evidence across distinct disease settings, initially demonstrated in the ASCENT trial where it prolonged progression-free survival and overall survival over standard chemotherapy in previously treated metastatic triple-negative breast cancer. Subsequent investigations have broadened its reach into first-line advanced treatment, including the ASCENT-03 trial evaluating monotherapy for patients ineligible for immune checkpoint inhibitors and the ASCENT-04/KEYNOTE-D19 trial pairing sacituzumab govitecan with pembrolizumab in PD-L1-positive tumors with a combined positive score of ten or greater. In parallel, the anti-HER2 conjugate trastuzumab deruxtecan has reshaped management for the HER2-low metastatic subpopulation, delivering a topoisomerase I inhibitor via a cleavable linker. However, these powerful modalities carry non-overlapping, agent-specific toxicities requiring stringent monitoring, such as severe neutropenia and diarrhea with sacituzumab govitecan, interstitial lung disease with trastuzumab deruxtecan, and stomatitis associated with datopotamab deruxtecan.

Targeting defective DNA damage repair represents another clinically validated tumor-intrinsic strategy, centered primarily on synthetic lethality induced by poly(ADP-ribose) polymerase inhibitors in germline BRCA1 and BRCA2 mutation carriers. Pivotal phase III trials, such as OlympiAD and EMBRACA, established significant progression-free survival improvements with olaparib and talazoparib monotherapies over cytotoxic chemotherapy in pretreated metastatic disease, while the OlympiA trial demonstrated significant invasive disease-free survival benefits in high-risk early-stage settings. In contrast, expanding PARP inhibition toward broader homologous recombination deficiency or BRCAness phenotypes remains largely exploratory and clinically unsettled, as illustrated by the TNT trial, which revealed that genomic scar scores failed to mirror the predictive fidelity of confirmed germline mutations. Furthermore, clinical durability is frequently constrained by acquired resistance mechanisms, such as secondary reversion mutations that restore open reading frames in BRCA genes, replication fork stabilization, and active drug efflux pumps. Rational combination regimens uniting PARP inhibitors with immune checkpoint blockade, ATR inhibitors, or anti-angiogenic agents like apatinib continue to undergo evaluation to overcome these adaptive pathways.

Precision efforts aimed at intracellular oncogenic signaling have focused extensively on the PI3K/AKT/mTOR axis, an essential network governing cellular metabolism, proliferation, and survival that is frequently hyperactivated in triple-negative breast cancer through PTEN loss or oncogenic mutations. Nevertheless, translating targeted pathway inhibition into unequivocal clinical survival has encountered substantial biological resistance and trial inconsistencies. While the phase II PAKT study demonstrated significant progression-free and overall survival improvements by combining the pan-AKT inhibitor capivasertib with paclitaxel, the subsequent phase III CAPItello 290 trial failed to meet its primary overall survival endpoint. A parallel divergence occurred with ipatasertib, where progression-free gains seen in the phase II LOTUS study failed to materialize in the phase III IPATunity130 trial, while neoadjuvant administration in FAIRLANE did not significantly elevate pathological complete response rates. Translational analyses reveal that static genomic mutations do not reliably capture dynamic, functional pathway dependence, highlighting the superior predictive value of active phosphoproteomic biomarkers such as phosphorylated AKT over simple sequencing profiles.

Targeting the androgen receptor in the luminal androgen receptor molecular subtype reflects a parallel effort to address unique tumor-intrinsic dependencies, although isolated androgen receptor inhibition yields modest clinical efficacy. Monotherapy trials using agents like enzalutamide or bicalutamide demonstrated clinical benefit in only a fraction of patients alongside brief progression-free intervals of approximately three months, demonstrating that isolated receptor blockade rapidly triggers compensatory signaling loops. Consequently, therapeutic development has pivoted toward dual inhibition strategies, including pairing enzalutamide with the PI3K inhibitor taselisib or investigating combinations with anti-PD-1 immunotherapy. Outside steroid hormone signaling, historical attempts to target frequently overexpressed surface receptors like EGFR using cetuximab, panitumumab, or erlotinib failed to surpass standard cytotoxic regimens due to extensive downstream signaling redundancy. Emerging cell-cycle interventions are therefore investigating alternative regulatory nodes, such as samuraciclib targeting CDK7, adavosertib targeting Wee1, and synthetic lethal inhibition of the DNA replication kinase Cdc7 in TP53-mutant tumors, illustrating a necessary transition toward biologically cooperative rather than single-agent pathway disruption.

The second layer of the proposed framework centers on the local immune and stromal microenvironment, where immune checkpoint inhibitors directed against PD-1 and PD-L1 have established pivotal roles in biomarker-defined settings. In early-stage, high-risk disease, the KEYNOTE-522 trial confirmed that integrating neoadjuvant pembrolizumab into platinum-containing chemotherapy and continuing it postoperatively significantly improves pathological complete response and event-free survival. Similarly, GeparNuevo demonstrated that short window-of-opportunity durvalumab immune priming enhanced long-term clinical survival despite producing modest pathological complete clearance gains. In advanced metastatic settings, successful deployment requires rigorous patient stratification; KEYNOTE-355 proved that first-line pembrolizumab combined with chemotherapy provides overall survival benefits exclusively in patients exhibiting PD-L1 combined positive scores of ten or greater, whereas KEYNOTE-119 established that late-line single-agent immunotherapy fails to surpass salvage chemotherapy. Furthermore, discordant findings between IMpassion130 and IMpassion131 emphasize that partner chemotherapy selection, corticosteroid premedication schedules, and specific immunohistochemical companion assays fundamentally govern whether an immune response is productively unleashed.

Beyond classical immune checkpoint inhibitors, microenvironmental modulation encompasses anti-vascular interventions, cellular therapies, and innate immune stimulation aimed at overcoming physical and immunological barriers to tumor clearance. Aberrant tumor vasculature generates hypoxia, acidosis, elevated interstitial fluid pressure, and physical exclusion of effector lymphocytes; however, vascular endothelial growth factor blockade via bevacizumab in the E2100 trial prolonged progression-free survival without yielding an overall survival benefit. Emerging combinations now pair multitargeted tyrosine kinase inhibitors like apatinib, famitinib, and sitravatinib with cytotoxic or immunotherapeutic backbones to exploit transient vascular normalization windows. Concurrently, exploratory cellular platforms including chimeric antigen receptor T-cell and natural killer cell therapies are undergoing refinement to overcome severe solid-tumor challenges, such as hostile stroma, immunosuppressive myeloid cells, and antigen escape. Additional novel approaches focus on innate immune reprogramming through pattern recognition receptor agonists, stimulator of interferon genes pathway activation, tumor-associated macrophage re-education, and personalized neoantigen peptide or messenger RNA vaccines designed to generate robust endogenous cytotoxic T-cell responses against heterogeneous clonal antigens.

The third biological layer recognizes that systemic macroenvironmental conditions across the host dynamically regulate therapy tolerance, peripheral inflammation, and therapeutic outcomes. The gut microbiota represents an influential host modifier whose compositional diversity, short-chain fatty acid production, and disruption via antibiotic administration correlate closely with systemic immune tone and variable treatment response. Simultaneously, chronic psychological stress and continuous neuroendocrine activation through the hypothalamic-pituitary-adrenal axis stimulate sustained glucocorticoid release, which can restrain antigen presentation, compromise T-cell activation, and foster an immunosuppressive systemic milieu. Moreover, host-level metabolic factors, such as insulin resistance, obesity, and circulating nutrient abundance, interact directly with tumor cell metabolic plasticity and immune competence. Investigational interventions exploring fasting-mimicking diets, specific amino acid restrictions, structured physical exercise regimens, and pharmacological metabolic regulators aim to restore systemic homeostasis and create an inhospitable macroenvironment for tumor survival, although researchers emphasize that these systemic interventions require rigorous prospective clinical validation before being classified as established oncologic targets.

Ultimately, transforming this three-layered biological model into durable patient survival depends on modern precision-enabling technologies and innovative clinical trial architectures. Minimally invasive liquid biopsy tracking circulating tumor DNA has emerged as a crucial tool for detecting molecular minimal residual disease, identifying emerging resistance alterations, and assessing real-time therapeutic response long before radiographic progression occurs. Complementing these circulating biomarkers, artificial intelligence platforms and machine learning algorithms are increasingly utilized to integrate complex multi-omics datasets, harmonizing genomic, transcriptomic, epigenomic, and digital pathology features into predictive models of therapeutic susceptibility. Realizing the full clinical potential of these biological and technological advances necessitates a decisive departure from traditional, rigid trial frameworks in favor of master protocols, including adaptive platform trials, biomarker-stratified umbrella designs such as the FUTURE study, and pathway-focused basket trials. By systematically synchronizing tumor vulnerabilities, microenvironmental conditions, and host physiology, modern oncology can transition from unselected cytotoxicity toward highly coordinated, adaptive multi-layer therapeutic regimens for triple-negative breast cancer.

Subject of Research: Multilevel biological framework and emerging therapeutic strategies for triple-negative breast cancer

Article Title: Current and future therapies for triple-negative breast cancer

Article References: Wang, Z.-X., Liu, X.-Y., Wu, Y.-X., Xiao, Y.-L., Ge, L.-P., Wu, S.-Y., Jiang, Y.-Z., & Shao, Z.-M. (2026). Current and future therapies for triple-negative breast cancer. Journal of Hematology & Oncology, 19(1), Article 57. https://doi.org/10.1186/s13045-026-01839-x

Image Credits: AI Generated

DOI: 10.1186/s13045-026-01839-x

Keywords: Triple-Negative Breast Cancer, Antibody-Drug Conjugates, Immune Checkpoint Inhibitors, PARP Inhibitors, Sacituzumab Govitecan, Trastuzumab Deruxtecan, PI3K-AKT-mTOR Pathway, Tumor Microenvironment, BRCA Mutations, Neoadjuvant Chemotherapy, Liquid Biopsy, Circulating Tumor DNA, Luminal Androgen Receptor, Host Macroenvironment, Adaptive Clinical Trials, Anti-Vascular Therapy, Precision Oncology